back to US directory
us clinical guidance

Uncomplicated chlamydial infection

CDC testing, site-specific treatment, pregnancy follow-up, partner management and repeat testing for uncomplicated chlamydial infection.

JurisdictionUnited States
Source check2026-08-20
Clinical reviewiatroX editorial team · Clinical editorial review · reviewed 2026-08-20 · due 2027-08-20
AudienceUnited States healthcare professionals
This is an iatroX educational summary of named United States sources, not an official guideline. It does not replace the complete source documents, local policy, specialist advice or clinical judgement. Use the named authority, current FDA labeling, applicable state law, payer rules and local protocol where relevant.

Scope of this summary

Adolescents and adults with uncomplicated genital, rectal or pharyngeal Chlamydia trachomatis infection, including pregnancy. Pelvic inflammatory disease, epididymitis, neonatal infection, lymphogranuloma venereum and disseminated or complicated disease require their dedicated CDC pathways.
sources for this section:CDC chlamydia 2021

The Bottom Line

  • Use a nucleic-acid amplification test at every exposed anatomic site; a urine or genital result alone does not assess rectal or pharyngeal exposure.
  • Doxycycline for seven days is the CDC preferred regimen for uncomplicated infection in nonpregnant adolescents and adults, with alternatives chosen only after adherence, pregnancy and contraindications are assessed.
  • In pregnancy, use a pregnancy-recommended regimen and obtain a nucleic-acid amplification test of cure about four weeks after treatment because persistent infection has maternal and neonatal consequences.
  • Advise no sexual contact until seven days after single-dose therapy or completion of a seven-day regimen, symptoms have resolved and recent partners have been treated.
  • Repeat testing about three months after treatment detects common reinfection; routine immediate test of cure is not advised for most nonpregnant patients unless adherence, symptoms or reinfection is in doubt.
sources for this section:CDC chlamydia 2021

Practical clinical workflow

1
Take a confidential history of symptoms, pregnancy possibility, exposed sites, recent partners, prior treatment, medication tolerance and barriers to completing a multiday regimen.
2
Collect site-specific nucleic-acid amplification tests and offer testing for gonorrhea, HIV and syphilis, adding pregnancy testing and examination when symptoms or history indicate.
3
Select the current CDC regimen for pregnancy status and infection site, check interactions and allergy history, and explain exactly when the treatment course is complete.
4
Arrange evaluation and presumptive treatment for partners with sexual contact during the preceding 60 days; use expedited partner therapy only where lawful and clinically appropriate.
5
Set reminders for pregnancy test of cure when applicable and retesting at three months, while addressing condoms, contraception, vaccination and access to confidential follow-up.
sources for this section:CDC chlamydia 2021

Safety boundaries and escalation

  • Pelvic or lower-abdominal pain, cervical-motion tenderness, fever or abnormal bleeding requires assessment for pelvic inflammatory disease rather than treatment as uncomplicated cervicitis alone.
  • Acute testicular pain or swelling requires urgent evaluation for torsion and epididymitis; do not rely on a positive chlamydia test to exclude a surgical emergency.
  • Proctocolitis, bloody discharge, ulcers or marked inguinal lymphadenopathy may indicate lymphogranuloma venereum and requires a longer, syndrome-specific pathway.
  • Persistent symptoms after treatment require review of adherence, reinfection, another pathogen and noninfectious causes; repeated empiric courses should not replace reassessment.
sources for this section:CDC chlamydia 2021

Localization

This page uses CDC regimens, US screening practice and state-dependent expedited-partner-therapy law. Laboratories, public-health reporting, minor-consent rules and access to confidential services differ by state and must be checked locally.
sources for this section:CDC chlamydia 2021

Source documents

Use the linked source documents for complete recommendations, evidence grading, exclusions and implementation detail.

  1. Centers for Disease Control and PreventionSexually Transmitted Infections Treatment Guidelines, 2021 — Chlamydial InfectionsMMWR 2021;70(No. RR-4) · published 2021-07-23 · accessed 2026-08-20
    view source
continue the learning

From guidance to deliberate practice and evidence

Choose what happens next. iatroX can carry this page's jurisdiction, source-check date and released version into an editable learning record, support your reflection, or let you browse the regional question bank while keeping this topic visible. No action records completion, starts a session or awards CPD/CME credit automatically.

Add this guidance review to CPD/CMEOpen an editable learning-log record with this page’s provenance attached. You confirm the activity, time, reflection and mappings.Reflect on this with TutorUse optional prompts to consider what you learned and what—if anything—you may change. Suggestions are never inserted automatically.Browse the US question bankKeep this guidance topic in view, then choose your exam and filters. No session starts automatically.
Found a source update or regional discrepancy? Tell the iatroX editorial team.